Document 0653
 DOCN  M9480653
 TI    [Ansatipine: only preventive treatment available for opportunistic MAI
       infections in AIDS. From an interview with Dr. Agnes Mignon]
 DT    9410
 AU    Mignon A; Laboratoires Pharmacia, Saint-Quentin-en-Yvelines.
 SO    Allerg Immunol (Paris). 1994 Apr;26(4):148, 151-3. Unique Identifier :
       AIDSLINE MED/94304498
 AB    Ansatipine, the international name of which is rifabutine, is a new
       specialty that was licensed in February 1993 and marketed in France in
       June 1993. It is an antibiotic of the rifamycin family, the result of
       research by Farmitalia Carlo Erba and is now presented by the
       Laboratoire Pharmacia. Today, rifabutine is the only molecule in the
       world that has been shown to be efficacious in preventative treatment
       for infections by the Mycobacterium avium complex (MAC) and to be
       officially recognised as such. Rifabutine (Ansatipine) was developed for
       prophylaxis of infections by MAC, because of its bacteriological
       activity on mycobacteria and especially on the Mycobacterium avium
       complex, the small number of the MAC which are naturally resistant, its
       high degree of tissue and intracellular penetration and its long
       half-life that allows a single daily dose. Clinical tests on more than
       1,000 patients have shown the benefit of Ansatipine in the prophylactic
       treatment of MAC infections: reduction by half on the frequency of
       surveillance, prolongation of the delay in appearance, significant
       improvement in general condition and quality of life of the patients.
       Ansatipine is now dispensed to town pharmacies, which can only ease the
       daily lives of patients and reinforce the co-operation between hospital
       teams and general practitioners who specialize in the care of AIDS.
 DE    AIDS-Related Opportunistic Infections/MICROBIOLOGY/*PREVENTION &
       CONTROL  Clinical Trials  English Abstract  Human  Mycobacterium
       avium-intracellulare Infection/*PREVENTION &  CONTROL  Pharmacies
       Quality of Life  Rifabutin/PHARMACOKINETICS/SUPPLY &
       DISTRIBUTION/*THERAPEUTIC USE  INTERVIEW  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).